Andras Farkas

Population pharmacokinetics and evaluation of the predictive performance of pharmacokinetic models in critically ill patients receiving continuous infusion meropenem: a comparison of eight pharmacokinetic models

Sofie Dhaese, Andras Farkas, Pieter Colin et al. · Journal of Antimicrobial Chemotherapy · 2018 · 51 citations · Full text

Pharmacodynamic Target Attainment for Cefepime, Meropenem, and Piperacillin-Tazobactam Using a Pharmacokinetic/Pharmacodynamic-Based Dosing Calculator in Critically Ill Patients

Emily L. Heil, David P. Nicolau, Andras Farkas et al. · Antimicrobial Agents and Chemotherapy · 2018 · 48 citations · Full text

Early target attainment of continuous infusion piperacillin/tazobactam and meropenem in critically ill patients: A prospective observational study

Sofie Dhaese, Alexander D.J. Thooft, Andras Farkas et al. · Journal of Critical Care · 2019 · 46 citations

Critical Care Management, Critical Care Medicine, Continuous Infusion Piperacillin/tazobactam +9

Comparison of the Accuracy and Precision of Pharmacokinetic Equations To Predict Free Meropenem Concentrations in Critically Ill Patients

Gloria Wong, Andras Farkas, Rachel Sussman et al. · Antimicrobial Agents and Chemotherapy · 2014 · 31 citations · Full text

Impact of the MIC of piperacillin/tazobactam on the outcome for patients with bacteraemia due to Enterobacteriaceae: the Bacteraemia-MIC project

Mercedes Delgado-Valverde, Eva Torres, Adoración Valiente-Méndez et al. · Journal of Antimicrobial Chemotherapy · 2015 · 26 citations · Full text